New study: Montreal researchers identify three drugs that could reduce mortality in severely ill COVID-19 patients
Researchers from the RI-MUHC and the McGill Genome Centre examine...
The RI-MUHC is first in Canada to adopt sentinel-free animal health monitoring
One of ten champion institutions in North America, the RI-MUHC has completely switched to a new program...
Type 1 diabetes: a combination therapy improves glucose control and performance of artificial pancreases
A publication in Nature Medicine by RI-MUHC researchers describes...
RI-MUHC leads study to identify a novel mechanism driving aggressive prostate cancer
This international research collaboration may lead to a shift in the clinical management of patients...
Improving the performance of rapid tests through clear instructions
Researchers at the RI-MUHC investigate whether rapid antigenic detection tests for COVID-19 could be adequately used in the workplace.
Five RI-MUHC researchers receive new funding from MI4
Cutting-edge projects in infection and immunity supported in Round 4 of MI4’s Seed Fund Grant program
Immunotherapy showing significant advancements in lung cancer treatment
Phase 3 clinical trial of neoadjuvant nivolumab leads to practice-changing results
The unexpected role of chloride channels in a rare neurological disorder
A new study finds mutations affecting the chloride channel of a glutamate transport protein in a rare disorder...
Where immune cells are located is critical for cancer immune therapy, a new study shows
An innovative new approach highlights the relevance of immune cells’ position within melanoma to inform on a...
TB and COVID-19, a joint battle?
On World TB Day 2022, we are looking at how researchers from the McGill International TB Centre at the RI-MUHC are working to raise awareness and to put an end to TB.